Clinical Trials Using Dexrazoxane Hydrochloride

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Dexrazoxane Hydrochloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-6 of 6
  • Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Location: 57 locations

  • Risk Classification Schemes in Identifying Better Treatment Options for Children and Adolescents with Acute Lymphoblastic Leukemia

    This randomized phase III trial studies risk classification schemes in identifying better treatment options for children and adolescents with acute lymphoblastic leukemia. Risk factor classification may help identify how strong treatment should be for patients with acute lymphoblastic leukemia.
    Location: 5 locations

  • Azacitidine or Decitabine in Epigenetic Priming in Patients with Newly Diagnosed Acute Myeloid Leukemia

    This randomized phase II trial studies how well azacitidine or decitabine work in epigenetic priming in patients with newly diagnosed acute myeloid leukemia. Azacitidine and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Doxorubicin Hydrochloride, Dexrazoxane Hydrochloride, and Olaratumab in Treating Patients with Advanced or Metastatic Soft Tissue Sarcoma That Cannot Be Removed by Surgery

    This phase II trial studies how well doxorubicin hydrochloride, dexrazoxane hydrochloride, and olaratumab work in treating patients with soft tissue sarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment and cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoprotective drugs, such as dexrazoxane hydrochloride, may protect normal cells from the side effects of chemotherapy. Monoclonal antibodies, such as olaratumab, may interfere with the ability of tumor cells to grow and spread. Giving doxorubicin hydrochloride, dexrazoxane hydrochloride, and olaratumab may work better in treating patients with soft tissue sarcoma.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

    This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma.
    Location: Childrens Oncology Group, Philadelphia, Pennsylvania

  • Calaspargase Pegol or Pegaspargase in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    This partially randomized phase II trial studies how well calaspargase pegol or pegaspargase works in treating younger patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as calaspargase pegol and pegaspargase, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether calaspargase pegol or pegaspargase works better in treating patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Location: 11 locations